Matt Kaeberlein is a Pathology Professor, a Genome Science Adjunct Scholar, and an Oral Health Studies Adjunct Expert at the University of Washington. His research interests are in basic aging mechanisms in order to support translational therapies that boost healthspan and quality of life. He has nearly 200 papers published in peer-reviewed journals and has received several prestigious awards, including the Breakthroughs in Gerontology Award, the Alzheimer’s Association Young Investigator Award, the Ellison Medical Foundation New Scholar in Aging Award, the Murdock Trust Award, the Pioneer in Aging Award, and the Vincent Cristofalo Rising Star in Aging Research.
Member of the American Association for the Advancement of Science, American Aging Association, and the Gerontological Society of America have also been awarded to Dr. Kaeberlein for his accomplishments. Dr. Kaeberlein has served on the Executive Committee and Board of Directors of the American Aging Association since 2012. He has also served on the Board of Directors of the Federation of American Societies for Experimental Biology and is now the Chair of the Gerontological Society of America’s Biological Sciences Section.
Read more about Matt kaerberlein here.
Inspiring Talks by Matt kaerberlein
- “This nonsense is often spouted by ignorant “longevity enthusiasts” who can’t be bothered to actually learn the science. There’s plenty of imagination, innovation, and big dreams in this field. In fact, I’d say the field is a magnet for scientists who push the envelope”
- “The message here is simple. Don’t be fooled by the spin and hype. Read past the abstract and actually look at the data.”
- “There are a lot of resources being put toward studying things with incremental or zero effects on aging. We only get so many shots on goal. IMO, we should be paying more attention to things that actually work reproducibly and robustly.”
- “Percent lifespan extension means nothing when the controls are short-lived. The next time someone Tweets about how “X increases lifespan in mice by Y percent!!!”, the first thing you should do is look at the absolute lifespan of the controls.”
- “I’ve come to believe peer-reviewers should be identified and disclose COIs upon publication of articles. Too many hidden COIs. Ever think “Who reviewed this!?” or “How did this get published in…?”. IMHO, it’s often because reviewers have a vested interest in that outcome.”
- “It’s starting to look like it’s possible to reverse aging and age-associated molecular changes in mice without actually extending lifespan or healthspan.”
- “You don’t have to be taking rapamycin (sirolimus) currently to participate in the UW Rapamycin Study. Former rapamycin users are encouraged to participate as well.”
- “If you or anyone you know is taking rapamycin (sirolimus), please encourage them to participate in our survey-based study.”
- “Real-world data from people taking rapamycin off label is critically important for understanding safety and potential efficacy.”
- “The UW Rapamycin Study is not to be confused with the “rapamycin registry”, in which I am not involved. The UW Rapamycin Study is IRB approved, HIPAA compliant, and will include a non-rapamycin group for comparison.”